Intraperitoneal Therapy for Ovarian Cancer

Affiliations

Comment

Franco M Muggia. J Clin Oncol. 2016.

. 2016 Mar 10;34(8):882.

doi: 10.1200/JCO.2015.62.8370. Epub 2016 Feb 1.

No abstract available

Comment in

Reply to F.M. Muggia.
Bookman MA, Brady MF. Bookman MA, et al. J Clin Oncol. 2016 Mar 10;34(8):884. doi: 10.1200/JCO.2015.63.4303. Epub 2016 Feb 1. J Clin Oncol. 2016. PMID: 26834059 No abstract available.
Reply to F.M. Muggia.
Chan JK, Monk BJ. Chan JK, et al. J Clin Oncol. 2016 Mar 10;34(8):882-3. doi: 10.1200/JCO.2015.63.4295. Epub 2016 Feb 1. J Clin Oncol. 2016. PMID: 26834062 No abstract available.

Intraperitoneal chemotherapy: long-term outcomes revive a long-running debate.
Bookman MA, Brady MF. Bookman MA, et al. J Clin Oncol. 2015 May 1;33(13):1424-6. doi: 10.1200/JCO.2014.60.2797. Epub 2015 Mar 23. J Clin Oncol. 2015. PMID: 25800752 No abstract available.
Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study.
Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, Monk BJ, Chan JK. Tewari D, et al. J Clin Oncol. 2015 May 1;33(13):1460-6. doi: 10.1200/JCO.2014.55.9898. Epub 2015 Mar 23. J Clin Oncol. 2015. PMID: 25800756 Free PMC article.